###begin article-title 0
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Transcriptional Regulation of PIK3CA Oncogene by NF-kappaB in Ovarian Cancer Microenvironment
###end article-title 0
###begin p 1
Conceived and designed the experiments: LZ GC. Performed the experiments: LZ NY JH Sl CL AO AB. Analyzed the data: SK LZ NY AG JG KH JH GC. Contributed reagents/materials/analysis tools: DK RB. Wrote the paper: LZ NY GC.
###end p 1
###begin p 2
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 258 265 258 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 558 565 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 603 609 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
PIK3CA upregulation, amplification and mutation have been widely reported in ovarian cancers and other tumors, which strongly suggests that PIK3CA is a promising therapeutic target. However, to date the mechanisms underlying PIK3CA regulation and activation in vivo is still unclear. During tumorigenesis, host-tumor interactions may play a critical role in editing the tumor. Here, we report a novel mechanism through which the tumor microenvironment activates the PIK3CA oncogene. We show that PIK3CA upregulation occurs in non-proliferating tumor regions in vivo. We identified and characterized the PIK3CA 5' upstream transcriptional regulatory region and confirmed that PIK3CA is transcriptionally regulated through NF-kappaB pathway. These results offer a new mechanism through which the tumor microenvironment directly activates oncogenic pathways in tumor cells.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 238 241 238 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Bader1">[1]</xref>
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Engelman1">[2]</xref>
###xml 248 251 248 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 253 256 253 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Parsons1">[4]</xref>
###xml 258 261 258 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vivanco1">[5]</xref>
###xml 263 266 263 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Hu1">[6]</xref>
###xml 268 271 268 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Testa1">[7]</xref>
###xml 440 443 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 445 448 445 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vanhaesebroeck1">[8]</xref>
###xml 560 563 560 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Sugimoto1">[9]</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Whitman1">[10]</xref>
###xml 703 706 703 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 708 711 708 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vanhaesebroeck1">[8]</xref>
###xml 822 825 822 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 827 830 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vivanco1">[5]</xref>
Phosphatidylinositol-3' kinase (PI-3 kinase) is an intracellular transducer with lipid substrate specificity implicated in a wide range of cancer-associated signaling pathways involved in tumor cell metabolism, survival and proliferation [1], [2], [3], [4], [5], [6], [7]. It is recruited and activated by multiple receptor tyrosine kinases and generates second messengers via phosphorylation of membrane inositol lipids at the D3 position [3], [8]. PI-3 kinase was first recognized as putative oncogene because of its ability to bind polyoma middle T antigen [9], [10]. Molecular cloning of PI-3 kinases revealed a large and complex family that contains three classes of multiple subunits and isoforms [3], [8]. However, how each subunit precisely contributes to the progress and maintenance of cancer is largely unknown [3], [5].
###end p 4
###begin p 5
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Chang1">[11]</xref>
###xml 351 357 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Campbell1">[12]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karakas1">[13]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Levine1">[14]</xref>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Nakayama1">[15]</xref>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Samuels1">[16]</xref>
###xml 530 534 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Shayesteh1">[17]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zhang1">[18]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Wenham1">[19]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Mok1">[20]</xref>
###xml 590 596 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 674 682 674 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 684 690 684 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 748 751 748 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Bader1">[1]</xref>
###xml 753 756 753 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Engelman1">[2]</xref>
###xml 758 761 758 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 763 766 763 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Parsons1">[4]</xref>
###xml 768 771 768 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vivanco1">[5]</xref>
###xml 773 776 773 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Testa1">[7]</xref>
###xml 822 828 822 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 977 983 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 230 246 <span type="species:ncbi:11955">avian retrovirus</span>
###xml 280 287 <span type="species:ncbi:9031">chicken</span>
The PIK3CA gene encodes the catalytic subunit p110-alpha, one of the three catalytic subunit proteins of the class IA PI-3 kinases that are usually activated by growth factor receptor tyrosine kinases. PIK3CA was identified as an avian retrovirus-encoded oncogene that transforms chicken embryo fibroblasts [11]. Numerous recent studies indicate that PIK3CA and downstream pathways are frequently targeted by genomic amplification, mutation or overexpression in solid tumors including ovarian cancer [12], [13], [14], [15], [16], [17], [18], [19], [20]. Previous studies on the function of PIK3CA have predominantly focused on regulatory circuitries within the cancer cell. In vitro, PIK3CA plays a critical role in cell survival and proliferation [1], [2], [3], [4], [5], [7]. However, to date it remains unknown whether PIK3CA assumes diverse roles depending on the state and/or the context in which the tumor cell is found. Furthermore, it remains unclear how such roles of PIK3CA might be affected by the tumor milieu.
###end p 5
###begin p 6
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Hanahan1">[21]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Joyce1">[22]</xref>
###xml 769 773 769 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Balkwill1">[23]</xref>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Balkwill2">[24]</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vakkila1">[25]</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Mantovani1">[26]</xref>
###xml 892 896 892 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lin1">[27]</xref>
###xml 898 902 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Nozawa1">[28]</xref>
###xml 904 908 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zijlstra1">[29]</xref>
###xml 1134 1138 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vakkila1">[25]</xref>
###xml 1140 1144 1136 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Luo1">[30]</xref>
###xml 1146 1150 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Greten1">[31]</xref>
###xml 1152 1156 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Pikarsky1">[32]</xref>
###xml 1158 1162 1154 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Coussens1">[33]</xref>
###xml 1164 1168 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karin1">[34]</xref>
###xml 1170 1174 1166 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">[35]</xref>
###xml 1344 1348 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Hanahan1">[21]</xref>
###xml 1350 1354 1346 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Joyce1">[22]</xref>
Dynamic interactions between genetic deregulation in tumor cells and reactive molecular and cellular changes in host cells populating the tumor microenvironment play a critical role in promoting malignant transformation and tumor progression and growth [21], [22]. Following the acquisition of critical genetic alterations, tumor cells are subjected to metabolic/ischemic stress and edit the surrounding microenvironment. In turn, host cells serve to edit the tumor, promoting the selection of tumor cells that benefit from tumor microenvironment influences. Innate and adaptive immune response mechanisms to tumors culminating in inflammation have received significant attention in this context, as inflammation has been shown to promote cancer growth and progression [23], [24], [25]. Tumor-associated leukocytes produce numerous proangiogenic factors promoting tumor vascularization [26], [27], [28], [29]. Furthermore, nuclear factor kappa-B (NF-kappaB), a critical transcriptional regulator of inflammation, has been shown to play a critical role in inflammation-driven carcinogenesis and to promote tumor growth and progression [25], [30], [31], [32], [33], [34], [35]. It has thus been postulated that the continuous and dynamic cross-talk between tumor cells and host cells ensures the survival of tumor cells and sustains tumor growth [21], [22]. The mutual effects of tumor-host interactions have been characterized with respect to angiogenesis. However, how tumor-host interactions affect directly tumor cells remains partly undetermined.
###end p 6
###begin p 7
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Jemal1">[36]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Mok1">[20]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Ozols1">[37]</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Berchuck1">[38]</xref>
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Ozols2">[39]</xref>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Agarwal1">[40]</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Bast1">[41]</xref>
###xml 519 533 519 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA in vivo</italic>
###xml 659 665 659 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 772 778 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 590 595 <span type="species:ncbi:9606">human</span>
Epithelial ovarian cancer (EOC), the most common ovarian malignancy, continues to be the leading cause of death among gynecological malignancies [36]. The lack of preventive strategies, early diagnostic methods and effective therapies to treat recurrent ovarian tumors creates a pressing need to understand its pathogenesis and to identify molecular targets for both diagnosis and therapy of EOC at different stage of disease progression [20], [37], [38], [39], [40], [41]. In this study, we examined the expression of PIK3CA in vivo and its relationship with the tumor microenvironment in human ovarian cancer. The identification and characterization of the PIK3CA 5' transcriptional regulatory region (TRR) together with functional validation experiments confirmed that PIK3CA is transcriptionally regulated by the microenvironment, through inflammation and NF-kappaB. These results offer a new mechanism through which the tumor microenvironment directly activates oncogenic pathways in tumor cells and promotes tumor growth.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Specimens
###end title 9
###begin p 10
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zhang2">[42]</xref>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
The specimens used in this study were collected at the University of Pennsylvania and the University of Turin, Italy [42]. Tissues were obtained after patients' written consent under a general tissue collection protocol approved by the institution's Institutional Review Board (IRB) of the University of Pennsylvania and the University of Turin. All tumors were from primary sites, and were collected at the time of debulking surgery from previously untreated patients with stage III and IV ovarian cancer. Samples were snap-frozen immediately and stored at -80degreesC. Specimens were collected under local Institutional review board approval and processed under procedures approved by the HIPAA act.
###end p 10
###begin title 11
Cell Culture
###end title 11
###begin p 12
###xml 90 96 <span type="species:ncbi:9913">bovine</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
Cells were cultured in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen). In some experiments cells were incubated in media enriched with recombinant human TNF-alpha (50 or 100 ng/ml, BD Bioscience, San Jose, CA) for various times as indicated.
###end p 12
###begin title 13
Total RNA Isolation and Quantitative Real-time RT-PCR
###end title 13
###begin p 14
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 450 476 450 476 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCA AAG GAT TGG GCA CTT TT</named-content>
###xml 498 524 498 524 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCC TCG ACT TGC CTA TTC AG</named-content>
###xml 421 426 <span type="species:ncbi:9606">Human</span>
Total RNA was isolated from 100 to 500 mg of frozen tissue or 1x106 cultured cells with TRIzol reagent (Invitrogen). After treatment with RNase-free DNase (Invitrogen), total RNA was reverse-transcribed using Superscript First-Strand Synthesis Kit for RT-PCR (Invitrogen) under conditions defined by the supplier. cDNA was quantified by real-time PCR on the ABI Prism 7900 Sequence Detection System (Applied Biosystems). Human PIK3CA forward primer: TCA AAG GAT TGG GCA CTT TT, and reverse primer: GCC TCG ACT TGC CTA TTC AG. PCR was performed using Sybr Green PCR Core reagents (Applied Biosystems, Foster City, CA) according to manufacturer's instructions. PCR amplification of the housekeeping gene GAPDH was performed for each sample as control for sample loading and to allow normalization among samples. A standard curve was constructed with PCR-II TOPO cloning vector (Invitrogen) containing the same inserted fragment and amplified by the real-time PCR.
###end p 14
###begin title 15
Tissue Microarray
###end title 15
###begin p 16
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Kononen1">[43]</xref>
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lassus1">[44]</xref>
The tissue microarray was constructed as described previously [43], [44]. In brief, tumors were embedded in paraffin and 5-microm sections were stained with hematoxylin-eosin to select representative regions for biopsies. Four core tissue biopsies were obtained from each specimen. The presence of tumor tissue on the arrayed samples was verified on hematoxylin-eosin stained section.
###end p 16
###begin title 17
Immunohistochemistry (IHC) and Image Analysis
###end title 17
###begin p 18
###xml 752 756 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zhang3">[45]</xref>
###xml 196 202 <span type="species:ncbi:9986">rabbit</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 251 257 <span type="species:ncbi:9986">rabbit</span>
###xml 263 268 <span type="species:ncbi:9606">human</span>
###xml 296 302 <span type="species:ncbi:9986">rabbit</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 355 360 <span type="species:ncbi:10090">mouse</span>
###xml 366 371 <span type="species:ncbi:9606">human</span>
###xml 399 402 <span type="species:ncbi:10116">rat</span>
###xml 408 413 <span type="species:ncbi:10090">mouse</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
###xml 439 444 <span type="species:ncbi:9606">human</span>
###xml 464 469 <span type="species:ncbi:10090">mouse</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 496 499 <span type="species:ncbi:10116">rat</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
IHC was performed using the VECTASTAIN ABC Kit as described by the manufacturer (Vector, Burlingame, CA). We used the following primary antibodies (all from BD Pharmingen unless noted otherwise): rabbit anti-human Ki67 (1:200, DAKO, Carpinteria, CA); rabbit anti-human cytokeratin (1:200, DAKO); rabbit anti-human p65 (1:400, Santa Cruz, Santa Cruz, CA); mouse anti-human p110alpha (1:250 or 1:50); rat anti-mouse CD31 (1:200); mouse anti-human HIF1Alpha (1:200); mouse anti-human c-Jun (1:200); rat anti-mouse CD11b (1:200). Antibodies were incubated for 2 hrs at room temperature or overnight at 4degreesC. The immunoreaction was visualized with 3,3'-diaminobenzidine (Vector). Double immunofluorescent staining was performed as previously described [45]. Briefly, sections were sequentially incubated in 5% normal serum; primary antibodies for 2 hrs; and fluorescent labeled secondary antibodies (Vector) for 30 min. Sections were counterstained with DAPI before being inspected under the fluorescent microscope. Images were collected through Cool SNAP Pro color digital camera (Media Cybernetics, Silver Spring, MD) and staining index was analyzed using Image-Pro Plus 4.1 software (Media Cybernetics).
###end p 18
###begin title 19
TUNEL Assay
###end title 19
###begin p 20
###xml 94 101 94 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 106 114 106 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The ApopTag peroxidase in situ detection kit (Intergen) was used to visualize apoptotic cells in vivo and in vitro. The procedure was performed according to manufacturer's instruction. Briefly, tumor tissue sections were fixed with 1% paraformaldehyde in PBS, followed by cold ethanol and acetic acid post-fixation. Following incubation with residues of digoxigenin nucleotide and terminal deoxynucleotide transferase for one hr at 37degreesC, cells were incubated with FITC-labeled anti-digoxigenin antibody.
###end p 20
###begin title 21
Plasmids
###end title 21
###begin p 22
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
The mouse PIK3CA cDNA was generously provided by Dr. Roberts (Harvard University). Mammalian expression plasmid pCDNA3 was from Invitrogen. To construct luciferase reporter plasmids, 5'TRRs of the human and mouse PIK3CA were amplified from BAC or genomic DNA using Expand High Fidelity PCR System (Roche, Indianapolis, IN) and inserted upstream of the luciferase gene in pGL3-Basic vector (Promega, Madison, WI). Sequences of 5'TRR in all these reporter constructs were verified by DNA sequencing.
###end p 22
###begin title 23
5' Rapid Amplification of cDNA Ends (5'RACE)
###end title 23
###begin p 24
Total RNA was extracted with the RNeasy Mini RNA kit (Qiagen, Valencia CA) and the 5' RACE system (Invitrogen) was used. The 5' RACE PCR product was inserted into the TA cloning system (Invitrogen).
###end p 24
###begin title 25
Plasmid Transfection
###end title 25
###begin p 26
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 466 472 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Cells were seeded in 6-well plates at 3x105 cells/well and grown overnight to approximately40% confluence prior to transfection. All plasmids were transfected with FuGENE6 transfection reagent (Roche) following the manufacturer's instructions. To select neomycin-resistant cells, 400 microg/ml neomycin (Invitrogen) was applied. For shRNA experiments, cells were transfected with siRNA expressing pLTsuppressor1.0. In vitro experiments indicated that suppression of PIK3CA mRNA persisted for up to 30 days. All transfection experiments were done in triplicate and repeated at least twice with different DNA isolates.
###end p 26
###begin title 27
Luciferase Reporter Assay
###end title 27
###begin p 28
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Cells were seeded in 6-well plates at 3x105 cells/well and grown overnight to 40% confluence prior to transfection. To test the promoter activity of PIK3CA, a total of 0.5 microg reporter construct and 0.01 microg pRL-TK internal control (Promega) were used for each transfection. All transfection experiments were done in triplicate and repeated at least twice with different DNA isolates. Forty-eight hours post-transfection, luciferase analysis was performed on Luminoskan Ascent (Thermo-Labsystems, Waltham, MA) using Dual-Luciferase Reporter Assay System (Promega) according to the manufacturers' instructions. For co-transfection experiments, 1 microg of each pCMV-IkappaBalpha or pCMV-IkappaBalphaM plasmid (CloneTech, Mountain View, CA) was used.
###end p 28
###begin title 29
Electrophoretic Mobility Shift Assay (EMSA)
###end title 29
###begin p 30
###xml 352 358 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 382 404 368 390 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GACGTGGGGGATTTTTCGCGTA</named-content>
###xml 421 427 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 459 460 441 442 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 451 473 433 455 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GACGTGGG<underline>C</underline>GATTTTTCGCGTA</named-content>
###xml 491 497 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 521 543 499 521 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCAGATAGACGAGACTTGAGTC</named-content>
###xml 587 608 561 582 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGTTGAGGGGACTTTCCCAGG</named-content>
###xml 610 614 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">[35]</xref>
###xml 663 664 633 634 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 655 676 625 646 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGTTGAGG<underline>C</underline>GACTTTCCCAGG</named-content>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
Nuclear extract from cells was prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents plus Halt Protease Inhibitor Cocktail Kit (Pierce, Rockford, IL) following the manufacturer's protocols and stored at -80degreesC until used. Recombinant NFkappaB (p50) was ordered from Promega. 5'-Biotin-labeled DNA oligos containing the wild-type human PIK3CA NFkappaB binding site (GACGTGGGGGATTTTTCGCGTA), mutated human PIK3CA NFkappaB binding site (GACGTGGGCGATTTTTCGCGTA), scramble human PIK3CA NFkappaB binding site (TCAGATAGACGAGACTTGAGTC), wild-type control NFkappaB binding site (AGTTGAGGGGACTTTCCCAGG) [35], mutated control NFkappaB binding site (AGTTGAGGCGACTTTCCCAGG) were synthesized and the two complementary oligos were annealed to obtain the double-stranded probe. EMSA was performed using LightShift Chemiluminescent EMSA Kit (Pierce). The nuclear extract (or p50) and 30 fmol of labeled probe were incubated in the 10x binding buffer plus 1 microg poly(dI-dC) in 20 microl reaction system at room temperature for 20 min. The entire 20 microl binding reaction was loaded on a 7.5% polyacrylamide gel and run at room temperature in 0.25x TBE at 110 V for 1-1.5 h. The electrophoresed binding reaction was then transferred to BrightStar-Plus positively charged Nylon membrane (Ambion, Austin, TX) in Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA) at 15 V for 30 min and cross-linked in UV Stratalinker 1800 (Stratagene, La Jolla, CA) at auto cross-link level for 1 min. Detection of Biotin-labeled DNA probe was performed strictly following the manufacturer's protocol.
###end p 30
###begin title 31
Chromatin Immunoprecipitation (ChIP)
###end title 31
###begin p 32
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 482 511 468 497 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCACCAAGACACTACCTTGAATC-3&#8242;</named-content>
###xml 516 545 502 531 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTCTGCAGTCCTTTGACTCACTT-3&#8242;</named-content>
###xml 586 612 572 598 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACACCATGGGGAAGGTGAA-3&#8242;</named-content>
###xml 617 643 603 629 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAGTAGGGACCTCCTGTTTC-3&#8242;</named-content>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 265 271 <span type="species:ncbi:9986">rabbit</span>
###xml 335 341 <span type="species:ncbi:9986">rabbit</span>
ChIP assay to detect p65 binding on the human PIK3CA promoter was performed using the Upstate ChIP assay kit (Upstate, Charlottesville, VA) following the manufacturer's instruction. Sheared DNA was incubated at 4degreesC overnight with 2 microg immunoprecipitating rabbit polyclonal IgG antibody to p65 (Santa Cruz) or 2 microg normal rabbit control IgG. Input and chromatin-immunoprecipitated DNA was used as PCR template for detection of p65 binding on the promoter (with primers 5'-GCACCAAGACACTACCTTGAATC-3' and 5'-CTCTGCAGTCCTTTGACTCACTT-3') or on the GAPDH promoter (with primers 5'-GACACCATGGGGAAGGTGAA-3' and 5'-GAGTAGGGACCTCCTGTTTC-3') using the PCR Core kit (Roche).
###end p 32
###begin title 33
Bioinformatics
###end title 33
###begin p 34
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Cartharius1">[46]</xref>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
A search for potential transcription factor binding sites on the human and mouse PIK3CA 5'TRRs were performed using the program Mat Inspector V2.2 at [46].
###end p 34
###begin title 35
Statistics
###end title 35
###begin p 36
Statistical analysis was performed using the SPSS statistics software package (SPSS). All results were expressed as mean +/- SD, and p<0.05 was used for significance.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
PIK3CA is upregulated in non-proliferating regions in ovarian cancer
###end title 38
###begin p 39
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 260 275 252 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 A to C</xref>
###xml 343 353 331 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 C</xref>
###xml 534 544 514 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 B</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 611 616 <span type="species:ncbi:9606">human</span>
To reveal spatial aspects of PIK3CA regulation in tumor in vivo, we first examined the expression of p110alpha in human ovarian cancer specimens. Interestingly, strong p110alpha expression was mainly detected in groups of non-proliferating, Ki67- tumor cells (Figure 1 A to C). In these cells, p110alpha was translocated to the cell membrane (Figure 1 C). In contrast, Ki67+ regions exhibited low expression of p110alpha, which was mainly located in the cytoplasm, while only few Ki67+ cells exhibited p110alpha at the cell membrane (Figure 1 B). A tissue microarray was used to further validate this result in human ovarian cancer. In 18 of 30 (60%) tumors, strong p110alpha expression (and membrane localization) was detected mainly in Ki67- tumor regions, while in the other tumors strong membrane p110alpha expression was either detected both in both Ki67- and Ki67+ tumor cells (5/30, 16.7%); mainly in Ki67+ tumor cells (3/30,10.0%); or it was undetectable (4/30; 13.3%).
###end p 39
###begin title 40
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo.</italic>
PIK3CA is upregulated in non-proliferating tumor cells in vivo.
###end title 40
###begin p 41
###xml 612 619 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1654 1660 1618 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 932 937 <span type="species:ncbi:9606">human</span>
###xml 1210 1215 <span type="species:ncbi:9606">human</span>
###xml 1500 1505 <span type="species:ncbi:9606">human</span>
A to C. Double immunostaining of p110alpha (green, FITC) and Ki67 (red, Texas Red) in human ovarian cancer B. High magnification of a region from A with low expression of p110alpha. p110alpha is expressed at low levels and localizes to the cytoplasm of Ki67-positive tumor cells. C. High magnification of a region from A with high expression of p110alpha. p110alpha is expressed at high levels and localizes to the plasma membrane in Ki67-negative tumor cells. D and E. Immunohistochemical localization of Ki67 allows for clear identification of areas of proliferating and areas of non-proliferating tumor cells in vivo in 2008 ovarian xenograft tumors. E. High magnification of area from D showing the boundary between a proliferating and a non-proliferating region. F to H. Strong expression and cell membrane localization of p110alpha is only found in Ki67-negative areas. F. Section adjacent to D, stained with antibody against human p110alpha (1:250 dilution). G. High magnification of area from F showing the boundary between proliferating and non-proliferating region. H. High magnification of area from G showing membrane localization of p110alpha in the non-proliferating region. I. Immunostaining of human cytokeratin identifies tumor cells in proliferating and non-proliferating areas in the 2008 xenograft model. The line traces the boundary between the two areas, as defined by Ki67 staining in adjacent section (see J). Both proliferating and non-proliferating regions are positive for human cytokeratin (FITC, green), indicating tumor cells. Cell nuclei were counterstained with DAPI. J to L. Double p110alpha and Ki67 immunostaining maps PIK3CA activation in proliferating or non-proliferating areas in 2008 xenograft tumors. J. Ki67 (red, Texas Red) and p110alpha (FITC, green) exhibit reciprocal expression. K and L. High magnification of proliferating region (I) and non-proliferating region (H) from J.
###end p 41
###begin p 42
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 259 275 259 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 D and E</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zhang4">[47]</xref>
###xml 453 468 449 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 F to H</xref>
###xml 540 550 532 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 H</xref>
###xml 707 722 695 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g001">Figure 1 I to K</xref>
###xml 927 935 907 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g002">Figure 2</xref>
###xml 953 959 933 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1042 1049 1022 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1203 1211 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g003">Figure 3</xref>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 1021 1026 <span type="species:ncbi:9606">human</span>
To further confirm this result, we investigated xenograft tumors generated with the 2008 ovarian cancer cell line. The advantage of this model is that distinct areas of proliferating and resting tumor cells can be clearly identified in vivo by Ki67 staining (Figure 1 D and E) [47]. Similarly to the reciprocal expression observed in the human specimens, strong p110alpha expression was detected in tumor cells only in Ki67-, non-proliferating regions (Figure 1 F to H). In these areas, p110alpha was mainly localized to the cell membrane (Figure 1 H). Double staining confirmed that areas expressing p110alpha were in fact populated by tumor cells, which expressed cytokeratin, an epithelial tumor marker (Figure 1 I to K). With increased primary antibody concentration (from 1:200 to 1:50), weak p110alpha expression could also be detected in Ki67+ regions, but p110alpha localized diffusely to the cytoplasm in these areas (Figure 2). Thus, oncogene PIK3CA is significantly upregulated in non-proliferating regions in human ovarian cancer in vivo. These non-proliferating regions always lack blood vessel support and contain numerous necrotic/apoptotic cells as well as rich lymphocyte infiltrating (Figure 3).
###end p 42
###begin title 43
###xml 60 68 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo.</italic>
p110alpha is overexpressed in non-proliferating tumor cells in vivo.
###end title 43
###begin p 44
A. Immunohistochemical staining of p110alpha using high primary antibody concentration (1:50) reveals low expression of p110alpha diffusely in the cytoplasm of tumor cells in Ki67-positive (Ki67+) regions. B and C. High magnification of non-proliferating (B) and proliferating (C) regions from A.
###end p 44
###begin title 45
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo.</italic>
PIK3CA is upregulated in undervascularized tumor areas in vivo.
###end title 45
###begin p 46
A. Double immunostaining of CD31 (red, Texas Red) and p110alpha (green, FITC) in the 2008 xenograft model. Strong p110alpha staining is mainly detected in tumor regions located distant from capillaries. B. Triple staining of p110alpha (red, Texas Red), Ki67 (blue, AMCA) and TUNEL (green, FITC) in the 2008 xenograft model.
###end p 46
###begin title 47
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 53 59 <span type="species:ncbi:10090">murine</span>
Identification and characterization of the human and murine PIK3CA promoters
###end title 47
###begin p 48
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 290 305 290 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4A and B</xref>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 546 552 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 631 640 631 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4A</xref>
###xml 677 686 677 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4B</xref>
###xml 733 739 733 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 786 800 786 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4C to E</xref>
###xml 814 820 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 947 955 947 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g005">Figure 5</xref>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 417 422 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 807 813 <span type="species:ncbi:10090">murine</span>
###xml 931 936 <span type="species:ncbi:9606">human</span>
To better understand the regulation signals contributing to upregulation of PIK3CA in cancer, 5' upstream regulatory sequences of the human PIK3CA gene were identified. 5'-rapid amplification of cDNA end (5'RACE) was employed to identify the transcription start site (TSS) of human PIK3CA (Figure 4A and B). A 125 bp segment of the 5'-untranslated region (UTR) and 2.3 Kbp of the TRR of human PIK3CA were cloned from human bacterial artificial chromosome (BAC, clone number: PR11-245C23). We found that the 5' upstream regulatory region of human PIK3CA is located approximately 50 Kbp upstream of the translation start codon site (Figure 4A). This region is highly rich in GC (Figure 4B). Mapping RT-PCR further confirmed the TSS of PIK3CA, and a small splicing variant was identified (Figure 4C to E). The murine PIK3CA 5' upstream regulatory sequence was also cloned by the same method, and was found to be 63.6% identity to the human sequence (Figure 5) and to include a small intron.
###end p 48
###begin title 49
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Identification and characterization of the human PIK3CA promoters.
###end title 49
###begin p 50
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 586 591 <span type="species:ncbi:9606">human</span>
A. Illustration of the structure of human PIK3CA gene and its 5' upstream regulatory region. B. A region highly rich in GC is found in the PIK3CA 5'TRR. C. Illustration of the primers used for mapping RT-PCR of the PIK3CA transcriptional start site (SST). D. Results of mapping RT-PCR. There is no band between the forward primer F1 located upstream of the SST and the reverse primer R located on exon 1 of PIK3CA. The right size bands could be detected between primer F2 or F3 (both located downstream of SST) and reverse primer R. E. A small splicing variant is found in the 5'UTR of human PIK3CA gene, which can also be detected by mapping RT-PCR (primers F2 and R). F. Summarized results of the transcriptional activity of PIK3CA TRR fragments.
###end p 50
###begin title 51
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Alignment of human and mouse PIK3CA transcriptional regulatory regions.
###end title 51
###begin p 52
###xml 282 291 282 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4F</xref>
###xml 463 472 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g004">Figure 4F</xref>
To further characterize the transcriptional activity of the promoter region, the entire 2.3 Kbp 5' TRR or incrementally truncated promoter fragments were subcloned together with a 316 or a 150 bp transcript region into the pGL-basic reporter vector to reveal luciferase expression (Figure 4F). Strong transcriptional activity was localized to the -2,340 to -159 bp region by luciferase assay, while transcriptional activity significantly decreased after -159 bp (Figure 4F).
###end p 52
###begin p 53
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 294 302 290 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g006">Figure 6</xref>
###xml 367 373 363 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Next, transcription factor binding sites were predicted on human PIK3CA 5'TRR in silico by GenomatiX (). Binding sites for numerous stress-associated transcription factors were found, including NF-kappaB; hypoxia-inducible factor (HIF); heat-shock protein (HSP); and activator protein 1 (AP1) (Figure 6). Thus, stress signals mediated by these factors might regulate PIK3CA expression in non-proliferating tumor cells in areas of decreased vascularization and increased lymphocyte-infiltrating.
###end p 53
###begin title 54
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
5' upstream regulatory sequence of the human PIK3CA gene.
###end title 54
###begin title 55
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
Expression and localization of candidate transcription factors in situ
###end title 55
###begin p 56
###xml 97 106 97 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 597 616 581 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g007">Figure 7 A, D and G</xref>
###xml 874 893 858 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g007">Figure 7 B, E and H</xref>
###xml 1029 1048 1009 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g007">Figure 7 C, F and I</xref>
###xml 1149 1159 1125 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g007">Figure 7 F</xref>
###xml 1190 1196 1166 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1290 1296 1258 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1314 1321 1282 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1410 1416 1378 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1433 1437 1401 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Hu2">[48]</xref>
###xml 1467 1473 1435 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1531 1537 1499 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
The expression and localization of three putative regulatory factors that emerged from the above in silico analysis, HIF1alpha; c-Jun, a member of the AP1 complex; and the p65 subunit of NF-kappaB, were screened in 2008 xenografts. Because function of these factors requires expression and nuclear translocation, we considered strong expression and nuclear localization indirect evidence of functional activation. Strong nuclear HIF1alpha expression was seen in patchy cell clusters in Ki67- regions. HIF1alpha protein was also detected in Ki67+ regions, but it mainly localized to the cytoplasm (Figure 7 A, D and G). c-Jun protein was strictly expressed in the boundaries between Ki67+ and Ki67- regions, where only nuclear staining was detected. Few scattered c-Jun-positive cells could also be detected in Ki67+ regions, but nuclear c-Jun was not seen in Ki67- regions (Figure 7 B, E and H). Strong nuclear localization of NF-kappaB/p65 protein was seen in the Ki67- regions and in Ki67+ areas adjacent to the Ki67- regions (Figure 7 C, F and I). Interestingly, strongest nuclear NF-kappaB/p65 was detected adjacent to areas of tissue necrosis (Figure 7 F). This data together with the PIK3CA promoter analysis suggest that HIF1alpha and NF-kappaB are implicated in the upregulation of PIK3CA in Ki67- regions in vivo. Consistent with this hypothesis, the hypoxia/HIF pathway has been reported to regulate PIK3CA in cancer cells [48]. Since hypoxic regulation of PIK3CA has been confirmed, we next focused on the regulation of PIK3CA by the NF-kappaB pathway.
###end p 56
###begin title 57
###xml 63 71 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ.</italic>
Expression and localization of candidate transcription factors in situ.
###end title 57
###begin p 58
A to C. Immunohistochemical staining of candidate transcription factors HIF1alpha, c-Jun and NF-kappaB in 2008 xenografts. The line shows the boundary between the Ki67+ p110alpha-low, and Ki67- p110alpha-high regions. D to F. High magnification from A to C, respectively, shows expression and nuclear localization of HIF1Alpha, c-Jun and NF-kappaB in 2008 xenografts. G to I. Illustration of the localization of the candidate transcription factors HIF1alpha, c-Jun and NF-kappaB in the 2008 xenograft model. Large dots represent cytoplasmic localization, while small dots represent nuclear localization. The line represents the boundary between the Ki67+ p110alpha-low, and Ki67- p110alpha-high regions.
###end p 58
###begin title 59
###xml 48 54 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
NF-kappaB binds to the promoter and upregulates PIK3CA expression
###end title 59
###begin p 60
###xml 61 67 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 140 146 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 155 164 147 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g008">Figure 8A</xref>
###xml 317 323 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 333 341 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 475 479 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karin1">[34]</xref>
###xml 481 485 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">[35]</xref>
###xml 697 703 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 876 892 796 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g008">Figure 8 B and C</xref>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 311 316 <span type="species:ncbi:9606">human</span>
Consistent with an important role of NF-kappaB in regulating PIK3CA, we found NF-kappaB binding site consensus sequences in human and mouse PIK3CA 5'TRRs (Figure 8A). The human promoter NF-kappaB binding site was located at -807 to -786 bp. We tested whether NF-kappaB regulates the transcriptional activity of human PIK3CA promoter in vitro. NF-kappaB activation requires release from its inhibitory subunit IkappaBalpha, which allows NF-kappaB translocation to the nucleus [34], [35]. Transient forced expression of wild-type IkappaBalpha or mutant IkappaBalpha (IkappaBalphaM), both of which bind NF-kappaB and block its translocation to the nucleus, attenuated the transcriptional activity of PIK3CA promoter, as revealed by luciferase assay. Removing the NF-kappaB binding site from the promoter region abrogated the inhibitory activity of IkappaBalpha or IkappaBalphaM (Figure 8 B and C).
###end p 60
###begin title 61
###xml 23 29 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
NF-kappaB binds to the PIK3CA promoter and activates its expression.
###end title 61
###begin p 62
###xml 90 96 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 190 196 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 499 505 471 477 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lane 1</underline>
###xml 549 555 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 571 577 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 602 615 566 579 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 2 and 3</underline>
###xml 622 628 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 662 668 622 628 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 4</underline>
###xml 711 724 667 680 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 5 and 6</underline>
###xml 736 742 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 776 782 728 734 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 7</underline>
###xml 833 846 781 794 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 8 and 9</underline>
###xml 859 865 807 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 959 965 899 905 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lane 1</underline>
###xml 972 978 912 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1002 1015 938 951 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 2 and 3</underline>
###xml 1022 1028 958 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1050 1056 982 988 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 4</underline>
###xml 1068 1074 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1098 1111 1026 1039 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 5 and 6</underline>
###xml 1123 1129 1051 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1151 1157 1075 1081 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 7</underline>
###xml 1190 1203 1110 1123 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 8 and 9</underline>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 74 80 <span type="species:ncbi:10090">murine</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 543 548 <span type="species:ncbi:9606">human</span>
A. Illustration of the predicted NF-kappaB binding site in human (top) or murine (bottom) PIK3CA promoter region. B. Illustration of the constructs comprising luciferase linked to the human PIK3CA promoter with (Luc-2340/316) or without the NF-kappaB binding site (Luc-378/316). C. Summary of luciferase activities of Luc-2340/316 and Luc-378/316 co-transfected with pCMV- IkappaBalpha or pCMV- IkappaBalphaM. D. Gelshift assay using ovarian cancer cell nuclear extract after TNF-alpha stimulation. Lane 1, NF-kappaB binding site of wild-type human PIK3CA promoter (wt huPIK3CA NF-kappaB probe) alone; lanes 2 and 3, wt huPIK3CA NF-kappaB probe+nuclear extract; lane 4, control NF-kappaB probe+nuclear extract, lanes 5 and 6, mutated huPIK3CA NF-kappaB probe+nuclear extract; lane 7, mutated control NF-kappaB probe+nuclear extract; lanes 8 and 9, scramble huPIK3CA NF-kappaB probe+nuclear extract. E. Gel shift assay using recombinant NF-kappaB/p50 protein. Lane 1, wt huPIK3CA NF-kappaB probe alone; lanes 2 and 3, wt huPIK3CA NF-kappaB probe+p50; lane 4, mutated huPIK3CA NF-kappaB probe alone; lanes 5 and 6, mutated huPIK3CA NF-kappaB probe+p50; lane 7, control NF-kappaB probe alone; lanes 8 and 9, control NF-kappaB probe+p50.
###end p 62
###begin p 63
###xml 54 60 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 296 302 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 389 399 377 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g008">Figure 8 D</xref>
###xml 586 592 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 603 613 583 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g008">Figure 8 E</xref>
###xml 671 677 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 290 295 <span type="species:ncbi:9606">human</span>
###xml 580 585 <span type="species:ncbi:9606">human</span>
The predicted NF-kappaB binding sequence in the human PIK3CA promoter was further tested using gel shift assay. Nuclear proteins from 2008 ovarian cancer cell line treated with TNF-alpha were able to shift (bind) oligonucleotide sequences containing the predicted NF-kappaB binding site of human PIK3CA promoter, but were not able to shift either mutant or mock oligonucleotide sequences (Figure 8 D). In addition, recombinant NF-kappaB/p50 protein was able to shift the oligonucleotide sequences containing the predicted NF-kappaB binding sites, confirming their presence in the human PIK3CA promoter (Figure 8 E). Finally, the presence of NF-kappaB binding site in the PIK3CA promoter was confirmed by chromosome immunoprecipitation assay (ChIP).
###end p 63
###begin title 64
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Inflammation might regulate PIK3CA expression via NF-kappaB pathway
###end title 64
###begin p 65
###xml 203 207 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vakkila1">[25]</xref>
###xml 209 213 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Coussens1">[33]</xref>
###xml 215 219 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karin1">[34]</xref>
###xml 221 225 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">[35]</xref>
###xml 463 473 451 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g009">Figure 9 A</xref>
###xml 627 642 611 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g009">Figure 9 B to D</xref>
During tumor growth, metabolic/ischemic stress induces tumor cell death, recruiting inflammatory cells including macrophages. These release proinflammatory cytokines which activate the NF-kappaB pathway [25], [33], [34], [35]. We mapped the distribution of necrosis, tumor-infiltrating macrophages and activation of NF-kappaB in the 2008 xenograft model. Morphologic necrosis was detected predominantly in Ki67- p110alpha+ regions, often located in their center (Figure 9 A). Brisk infiltration of CD11b+ macrophages, which produce pro-inflammation cytokines such as TNF-alpha, was found in association with areas of necrosis (Figure 9 B to D).
###end p 65
###begin title 66
###xml 20 26 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
TNF-alpha regulates PIK3CA expression via NF-kappaB pathway.
###end title 66
###begin p 67
###xml 497 503 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 892 898 880 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1035 1041 1019 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 113 119 <span type="species:ncbi:10090">murine</span>
A. H&E staining of 2008 tumor reveals a prominent area of necrosis (N). B and C. Immunohistochemical staining of murine CD11b reveals macrophage infiltrate in a 2008 xenograft. CD11b+ cells infiltrate tumors in Ki67-negative regions in proximity of necrosis. C. High magnification from B. D. Double immunostaining of CD11b (green, FITC) and Ki67 (red, Texas Red) reveals CD11b+ macrophages mainly in non-proliferating Ki67-negative regions. E. ChIP analysis of NF-kappaB binding to the endogenous PIK3CA promoter. The arrows indicate the positions of the primers flanking -803 NF-kappaB binding site that were used in the ChIP assays. Cells were treated with TNF-alpha for 0, 30, or 90 min, and then chromatin protein-DNA complexes were cross-linked using formaldehyde. The purified nucleoprotein complexes were immunoprecipitated with p65 antibody or non-immune IgG and amplified by PCR. F. PIK3CA mRNA expression levels after stimulation with pro-inflammatory cytokine TNF-alpha. G. Illustration of the transcriptional regulation of PIK3CA by NF-kappaB.
###end p 67
###begin p 68
###xml 341 345 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Smith1">[49]</xref>
###xml 347 351 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Kull1">[50]</xref>
###xml 353 357 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vercammen1">[51]</xref>
###xml 480 486 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 521 528 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 608 614 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 700 706 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 855 864 803 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g009">Figure 9E</xref>
###xml 877 883 825 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1019 1025 955 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1071 1080 1007 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro.</italic>
###xml 1111 1117 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1162 1171 1098 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g009">Figure 9F</xref>
###xml 1315 1321 1251 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1371 1378 1303 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 115 121 <span type="species:ncbi:10090">murine</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 310 315 <span type="species:ncbi:9606">human</span>
###xml 325 330 <span type="species:ncbi:9606">human</span>
TNF-alpha one of major cytokines produced by tumor-associated macrophages, is known to activate NF-kappaB. Because murine TNF-alpha is 69% identical and 85% homologous to human TNF-alpha, and it is known to bind to the human TNF-alpha receptor with the same affinity and to produce similar biologic effects on human cells as human TNF-alpha [49], [50], [51], we hypothesized that macrophage-derived TNF-alpha could be in part responsible for the observed NF-kappaB activation and PIK3CA upregulation in 2008 tumors cells in vivo. First, we tested whether TNF-alpha increases NF-kappaB complex binding to the PIK3CA promoter using the ChIP assay. Antibody to NF-kappaB/p65 was able to precipitate the PIK3CA promoter sequence and this was increased in a time-dependent manner by TNF-alpha treatment, which increases NF-kappaB translocation to the nucleus (Figure 9E). Thus, the PIK3CA promoter contains a functional NF-kappaB binding site and can be activated by NF-kappaB. Lastly, we tested whether TNF-alpha increased PIK3CA mRNA expression in ovarian cancer cell lines in vitro. A significant upregulation of PIK3CA was found in two ovarian cancer cell lines (Figure 9F). Taken together, our results indicate that inflammation triggered in response to tumor cell death might one of the mechanisms that upregulate PIK3CA expression via NF-kappaB in ovarian cancer cells in vivo.
###end p 68
###begin title 69
Discussion
###end title 69
###begin p 70
###xml 121 124 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Bader1">[1]</xref>
###xml 126 129 126 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Engelman1">[2]</xref>
###xml 131 134 131 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Katso1">[3]</xref>
###xml 136 139 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Parsons1">[4]</xref>
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vivanco1">[5]</xref>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 438 445 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 565 571 565 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 630 637 630 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 237 242 <span type="species:ncbi:9606">human</span>
PI-3 kinases are intracellular lipid kinases implicated in the regulation of cell metabolism, survival and proliferation [1], [2], [3], [4], [5]. In this study, we characterized the expression and transcriptional regulation of PIK3CA in human ovarian caner in vivo. We reported the spatial dissociation between tumor cell proliferation and PIK3CA upregulation, and a specialized functional role of PIK3CA in non-proliferating tumor cells in vivo. The identification and characterization for the first time of the PIK3CA 5' upstream regulatory region confirmed that PIK3CA is an important mediator of tumor cell response to stress in vivo and enabled the identification of a molecular link between inflammation and tumor growth mediated by NF-kappaB and p110alpha.
###end p 70
###begin p 71
###xml 9 18 9 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 223 229 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 333 347 329 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA in vivo</italic>
###xml 396 402 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 459 463 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Hu2">[48]</xref>
###xml 594 600 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 719 725 699 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 907 914 875 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Based on in silico prediction and in situ scanning, at least two stress signaling pathways appeared to play important roles in PIK3CA regulation in cancer, namely HIF and NF-kappaB. HIF binding sites were identified in the PIK3CA promoter region and strong nuclear HIF staining was detected in the areas where tumor cells upregulate PIK3CA in vivo. This is in agreement with recent evidence that PIK3CA is upregulated by hypoxia in renal carcinoma cell lines [48]. The second regulatory pathway mediated by NF-kappaB was characterized in this study. We confirmed NF-kappaB binding sites on the PIK3CA promoter by gel shift; documented binding of NF-kappaB through ChIP; and showed increased binding of NF-kappaB to the PIK3CA promoter by TNF-alpha. The use of the 2008 xenograft model enabled us to confirm that activation of NF-kappaB coincides with p110alpha upregulation in non-proliferating tumor cells in vivo.
###end p 71
###begin p 72
###xml 96 100 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vakkila1">[25]</xref>
###xml 102 106 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Luo1">[30]</xref>
###xml 108 112 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Greten1">[31]</xref>
###xml 114 118 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Pikarsky1">[32]</xref>
###xml 120 122 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Coussens1">33</xref>
###xml 124 126 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karin1">34</xref>
###xml 128 130 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">35</xref>
###xml 347 351 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Vakkila1">[25]</xref>
###xml 353 357 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Lenardo1">[35]</xref>
###xml 653 657 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Karin1">[34]</xref>
###xml 732 738 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1100 1104 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Degenhardt1">[52]</xref>
NF-kappaB plays a critical role in inflammation-driven tumor formation, growth, and progression [25], [30], [31], [32], 33, 34, 35. In the classical pathway, NF-kappaB activation is triggered in response to proinflammatory cytokines that lead to phosphorylation-induced IkappaB degradation and liberation of NF-kappaB p50:RelA or p50:c-Rel dimers [25], [35]. NF-kappaB activation promotes transcription of diverse genes encoding inflammatory cytokines, growth factors and cell adhesion molecules, which can promote tumor growth. Importantly, NF-kappaB activation may also promote tumor cell survival directly through inhibition of apoptosis or necrosis [34]. The present data offers the evidence that NF-kappaB directly upregulates PIK3CA and provides a novel pathway through which NF-kappaB activation can promote cancer cell survival during stress. Interestingly, activation of the PI-3 kinase/Akt/mTOR pathway has been previously shown to suppress autophagy and direct apoptosis-resistant tumor cells under stress to necrotic cell death, which results in inflammation and accelerated tumor growth [52].
###end p 72
###begin p 73
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 340 349 340 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001758-g009">Figure 9G</xref>
###xml 373 379 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 583 589 579 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1121 1127 1113 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
The present results provide novel in vivo evidence to support the concept that tumor-host interactions contribute to oncogene activation and tumor growth. Based on these findings and previously reported evidence, we propose a novel model to interpret the function of PIK3CA in solid tumors and its regulation by the tumor microenvironment (Figure 9G). During tumor growth, PIK3CA may be expressed at low levels and p110alpha localizes mainly to the cytoplasm in cancer cells proliferating in proximity to vessels in a metabolically lush microenvironment. This "physiologic" level of PIK3CA expression serves as an intracellular mediator maintaining tumor cell proliferation and growth by responding to extracellular growth factors. As tumor cells outgrow nutrient support, cancer cells are subjected to metabolic/ischemic stress ultimately leading to cell death. The paracrine factors released by stressed cells as well as infiltrating-leucocytes can edit the microenvironment towards inflammation. Our data suggest that the inflammatory microenvironment can edit back the tumor cells through activation of the NF-kappaB/PIK3CA pathway, with multifaceted results that promote survival.
###end p 73
###begin p 74
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 336 342 336 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001758-Zhang5">[53]</xref>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 686 692 686 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 442 447 <span type="species:ncbi:9606">human</span>
In summary, we demonstrated a specialized upregulation of PIK3CA oncogene in non-proliferating tumor cells induced by the microenvironment through inflammation. Non-proliferating tumor cells may contribute to resistance to current cancer therapeutics and could be an important source for tumor recurrence. Isoform-specific targeting of PIK3CA by small molecule inhibitors or siRNA can significantly block tumor growth and induce apoptosis in human cancer cells [53]. Thus, PIK3CA-targeted cancer therapy might be a rational approach to target non-proliferating tumor cells and enhance the effect of chemotherapy or radiation in combinatorial therapy. Furthermore, based on our results, PIK3CA targeting might be a rational approach to combine with anti-inflammatory cancer therapy.
###end p 74
###begin p 75
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
We thank Drs. Steven Johnson and Kang-Shen Yao (University of Pennsylvania) for the human ovarian cancer cells; and Dr. Thomas M. Roberts (Harvard University) for the mouse PIK3CA cDNA plasmid.
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
Oncogenic PI3K deregulates transcription and translation.
###end article-title 77
###begin article-title 78
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
###end article-title 78
###begin article-title 79
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
###end article-title 79
###begin article-title 80
Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
###end article-title 80
###begin article-title 81
###xml 49 54 <span type="species:ncbi:9606">human</span>
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
###end article-title 81
###begin article-title 82
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
###end article-title 82
###begin article-title 83
AKT signaling in normal and malignant cells.
###end article-title 83
###begin article-title 84
Synthesis and function of 3-phosphorylated inositol lipids.
###end article-title 84
###begin article-title 85
###xml 18 36 <span type="species:ncbi:11886">Rous sarcoma virus</span>
Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol.
###end article-title 85
###begin article-title 86
Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation.
###end article-title 86
###begin article-title 87
###xml 18 25 <span type="species:ncbi:9031">chicken</span>
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
###end article-title 87
###begin article-title 88
Mutation of the PIK3CA gene in ovarian and breast cancer.
###end article-title 88
###begin article-title 89
###xml 35 40 <span type="species:ncbi:9606">human</span>
Mutation of the PIK3CA oncogene in human cancers.
###end article-title 89
###begin article-title 90
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
###end article-title 90
###begin article-title 91
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
###end article-title 91
###begin article-title 92
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers.
###end article-title 92
###begin article-title 93
PIK3CA is implicated as an oncogene in ovarian cancer.
###end article-title 93
###begin article-title 94
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
###end article-title 94
###begin article-title 95
Molecular aspects of ovarian cancer.
###end article-title 95
###begin article-title 96
Biomarker discovery in epithelial ovarian cancer by genomic approaches.
###end article-title 96
###begin article-title 97
The hallmarks of cancer.
###end article-title 97
###begin article-title 98
Therapeutic targeting of the tumor microenvironment.
###end article-title 98
###begin article-title 99
Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
###end article-title 99
###begin article-title 100
Cancer: an inflammatory link.
###end article-title 100
###begin article-title 101
Inflammation and necrosis promote tumour growth.
###end article-title 101
###begin article-title 102
Role of tumor-associated macrophages in tumor progression and invasion.
###end article-title 102
###begin article-title 103
Role of infiltrated leucocytes in tumour growth and spread.
###end article-title 103
###begin article-title 104
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.
###end article-title 104
###begin article-title 105
###xml 119 124 <span type="species:ncbi:9606">human</span>
Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells.
###end article-title 105
###begin article-title 106
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.
###end article-title 106
###begin article-title 107
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
###end article-title 107
###begin article-title 108
NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
###end article-title 108
###begin article-title 109
Inflammation and cancer.
###end article-title 109
###begin article-title 110
NF-kappaB in cancer: from innocent bystander to major culprit.
###end article-title 110
###begin article-title 111
NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.
###end article-title 111
###begin article-title 112
Cancer statistics, 2007.
###end article-title 112
###begin article-title 113
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
###end article-title 113
###begin article-title 114
Discussion: Ovarian Cancer Prevention.
###end article-title 114
###begin article-title 115
Focus on epithelial ovarian cancer.
###end article-title 115
###begin article-title 116
Ovarian cancer: strategies for overcoming resistance to chemotherapy.
###end article-title 116
###begin article-title 117
Prevention and early detection of ovarian cancer: mission impossible?
###end article-title 117
###begin article-title 118
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 118
###begin article-title 119
Tissue microarrays for high-throughput molecular profiling of tumor specimens.
###end article-title 119
###begin article-title 120
Distinct subtypes of serous ovarian carcinoma identified by p53 determination.
###end article-title 120
###begin article-title 121
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
###end article-title 121
###begin article-title 122
MatInspector and beyond: promoter analysis based on transcription factor binding sites.
###end article-title 122
###begin article-title 123
###xml 28 38 <span type="species:ncbi:7227">Drosophila</span>
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.
###end article-title 123
###begin article-title 124
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.
###end article-title 124
###begin article-title 125
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 33 39 <span type="species:ncbi:10090">murine</span>
Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors.
###end article-title 125
###begin article-title 126
Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity.
###end article-title 126
###begin article-title 127
###xml 21 27 <span type="species:ncbi:10090">murine</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 153 159 <span type="species:ncbi:10090">murine</span>
Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF.
###end article-title 127
###begin article-title 128
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.
###end article-title 128
###begin article-title 129
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
###end article-title 129
###begin p 130
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 130
###begin p 131
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NCI P01-CA83638 SPORE in Ovarian Cancer (Career Development Award, LZ); the Ovarian Cancer Research Fund (GC and LZ); Mary Kay Ash Charitable Foundation (LZ) and the American Cancer Society (LZ). AG was supported in part by a predoctoral fellowship from the Hellenic Ministry of Education (Program HERACLITOS, EPEAEK). DK was partly supported by the Italian Association for Cancer Research (AIRC).
###end p 131

